700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
License Agreement with Pfizer for Matrix-M Technology
Investor Presentation
Reports Third Quarter 2025 Financial Results and Operational Highlights
Completes U.S. Marketing Authorization Transfer for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax, Inc. Enters Material Agreement with AstraZeneca for Facility Lease
Continues to Deliver on Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Definitive Additional Information Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Definitive Revised Proxy Statement
Free Writing Prospectus
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence